Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bavarian Nordic’s Imvamune found effective in smallpox studies
The study showed that a single vaccination of Imvamune could protect a variety of immune suppressed animals on the same day as a lethal challenge with Ectromelia virus;
The study showed that a single vaccination of Imvamune could protect a variety of immune suppressed animals on the same day as a lethal challenge with Ectromelia virus;
PPA Technologies is developing a technical solution for active support in cases of cardiac insufficiency and complete temporary support during cardiac arrest. This technology could be complementary to
Under the terms of the agreement, HP will manage Nycomed’s data centers, including more than 450 servers and 120 terabytes (TB) of storage and back-up facilities. HP will
Mr Kolker most recently held the position of group vice president and corporate controller in both the company and Taro USA, and also served as the company’s interim
The study was conducted on 16 rabbits that underwent open gynaecologic surgery in a uterine horn model. In preclinical testing, company’s fibrin sealant was found to be significantly
In the study, patients were dosed once a day for up to six months with either a 6mg IoGen tablet or placebo. There was no statistically significant difference
Joseph Mollica, chairman of the board, will assume day-to-day leadership responsibilities on an interim basis until a successor is appointed. A search will be undertaken to identify a
BSI-201, the first poly ADP-ribose polymerase (PARP) inhibitor in BiPar’s DNA repair portfolio, crosses the blood-brain barrier, a unique property that enables its targeted investigation in the brain
Under the terms of the acquisition, CeNeS shareholders will receive 0.3521 new Paion shares for each CeNeS share held. Based on the Xetra closing price of a Paion
In collaboration with four prestigious neurologists, Pivotal has begun screening patients for the Phase I research effort, which is expected to have major implications for the treatment of